Paragraph 28A Application by pre-assessment of modulesF1
Where an applicant for a United Kingdom marketing authorisation submits material in accordance with regulation 50(5) of the Human Medicines Regulations for pre-assessment by the licensing authority rather than as part of the submission of a full application for that marketing authorisation, the fee payable in respect of pre-assessment of each of the following Modules (as defined in Annex I to the 2001 Directive) is—
F2£31,049 in respect of Module 3 (chemical, pharmaceutical and biological information);
£31,049 in respect of Module 4 (non-clinical reports);
£31,049 in respect of Module 5 (clinical study reports).
Where an applicant for a United Kingdom marketing authorisation for a similar biological medicinal product submits material in accordance with regulations 53, 53A or 53B of the Human Medicines Regulations for pre-assessment of a complex abridged application by the licensing authority rather than as part of the submission of a full application for that marketing authorisation, the fee payable in respect of pre-assessment of each of the following Modules (as defined in Annex I to the 2001 Directive) is—
F3£5,802 in respect of Module 3 (chemical, pharmaceutical and biological information);
£5,802 in respect of Module 4 (non-clinical reports);
£5,802 in respect of Module 5 (clinical study reports).
The fee payable under sub-paragraphs (1) and (2) must be paid within a period of 14 days, commencing on the date of the written notice issued by the licensing authority requiring payment of the fee.
Where a fee has been paid under this paragraph, any fee payable under regulation 12(1) in connection with an application for the grant of a United Kingdom marketing authorisation in respect of the same product is reduced by the amount paid under this paragraph provided that no further assessment of the Module concerned is required.
Annotations
Textual amendments
- F1
Sch. 2 para. 28A inserted by S.I. 2019/775, Sch. 1 para. 7(8A) (as inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(g)(vi))
- F2
Sum in Sch. 2 para. 28A(1)(a)-(c) substituted (1.4.2025) by The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025 (S.I. 2025/317), regs. 1(2), 27(6)(a)
- F3
Sum in Sch. 2 para. 28A(2)(a)-(c) substituted (1.4.2025) by The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025 (S.I. 2025/317), regs. 1(2), 27(6)(b)